Compare AstraZeneca plc (AZN) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Xpeng Inc - ADR — how do they compare? AstraZeneca plc trades at $158.47 (market cap $248.14B), while Xpeng Inc - ADR trades at $11.76 (market cap $11.15B). The key difference: AstraZeneca plc is far larger — about 22.3× Xpeng Inc - ADR's market cap, and AstraZeneca plc pays a 2.01% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| AZN | XPEV | |
|---|---|---|
Market Cap | $248.14B | $11.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $28.07 |
52-Week Low | $147.06 | $11.68 |
Enterprise Value | $275.41B | $13.28B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
XPeng (XPEV) trades at $11.74, down 2.17% today, with a bearish technical signal but oversold RSI. Revenue surged to $76.72B in 2025, yet net losses persist at -$1.14B. Recent news highlights July 2026 deliveries of 38,027 vehicles, up 4% YoY, and expansion into robotics and autonomous driving.
Outlook: Analyst consensus is bullish with a $17.00 price target, but risks include intense EV competition and ongoing profitability challenges. Upside hinges on new model success and global expansion, while cash flow volatility and high debt remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
